Condition (MeSH)
Leukemia, Erythroblastic, Acute
ClinicalTrials.gov lists 175 trials for Leukemia, Erythroblastic, Acute or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 43.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
175 of the 175 trials are tagged with Leukemia, Erythroblastic, Acute itself; the rest are tagged with a narrower condition beneath it.
When did Leukemia, Erythroblastic, Acute trials start? (26)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Not applicable
- Observational
- Expanded access
Top of scale: 16
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2022 | 1 |
| 2020 | 1 |
| 2016 | 1 |
| 2015 | 2 |
| 2014 | 7 |
| 2013 | 8 |
| 2012 | 5 |
| 2011 | 14 |
| 2010 | 10 |
| 2009 | 5 |
Showing 10 of 26 earlier years.
No forecast is made for this condition: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 175 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Leukemia, Erythroblastic, Acute trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 48 |
| Phase 1/2 | 11 |
| Phase 2 | 71 |
| Phase 2/3 | 2 |
| Phase 3 | 22 |
| Not applicable | 5 |
| Observational | 15 |
| Expanded access | 1 |
How many Leukemia, Erythroblastic, Acute trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Active, not recruiting | 3 |
| Completed | 127 |
| Terminated | 27 |
| Withdrawn | 4 |
| No longer available | 1 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Leukemia, Erythroblastic, Acute trials? (6)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 43 |
| SWOG Cancer Research Network | 11 |
| European Organisation for Research and Treatment of Cancer - EORTC | 8 |
| Eastern Cooperative Oncology Group | 6 |
| ECOG-ACRIN Cancer Research Group | 4 |
Showing 5 of 6 sponsors.
Which drugs are being tested for Leukemia, Erythroblastic, Acute? (4)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Mitoxantrone | 22 |
| Busulfan | 22 |
| Cytoxan | 19 |
| Tipifarnib | 11 |
Interventions as named in the registry (11)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Cytarabine IT | 74 |
| Etoposid | 30 |
| Daunorubicine | 25 |
| Filgrastime (G-CSF) | 23 |
| Idarubicina | 23 |
Showing 5 of 11 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Leukemia, Erythroblastic, Acute trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Platelet count decreased | 1,530 | 9 |
| Neutrophil count decreased | 1,485 | 10 |
| Anemia | 1,404 | 7 |
| White blood cell decreased | 1,202 | 6 |
| Febrile neutropenia | 912 | 19 |
Showing 5 of 10 adverse events.
Which publications cover Leukemia, Erythroblastic, Acute? (15)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study. | International journal of molecular sciences | 2017 | Yes |
| Ethyl acetate extract and its major constituent, isorhamnetin 3-O-rutinoside, from Nitraria retusa leaves, promote apoptosis of human myelogenous erythroleukaemia cells. | Cell proliferation | 2011 | Yes |
| From mice to human: the "two-hit model" of leukemogenesis. | Cell cycle (Georgetown, Tex.) | 2006 | Yes |
| Effects of trichostatins on differentiation of murine erythroleukemia cells. | Cancer research | 1987 | Yes |
| Smad2/3-pathway ligand trap luspatercept enhances erythroid differentiation in murine β-thalassaemia by increasing GATA-1 availability. | Journal of cellular and molecular medicine | 2020 | No |
Showing 5 of 15 publications.
Prevalence (6)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Acute erythroid leukemia | Point prevalence | Unknown | Worldwide | Not stated | Unspecified |
| Acute erythroid leukemia | Point prevalence | Unknown | Worldwide | Not stated | Exact |
| Acute erythroid leukemia | Annual incidence | Unknown | Worldwide | Not stated | Exact |
| Acute erythroid leukemia | Annual incidence | Unknown | Worldwide | Not stated | Exact |
| Acute erythroid leukemia | Annual incidence | Unknown | Worldwide | Not stated | Unspecified |
Showing 5 of 6 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Acute erythroid leukemia | 318 | Exact | Orphadata Science knowledge files, Product 1 |
| Acute erythroid leukemia | 318 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.